Thank you, to for review and and you, XXXX. thank us. to progress morning of the good Lucinda, you third I'm joining for quarter pleased our all
to evolving into remained X, situation quarter. May, Before summarizing I period and a our like stable its on program COVID-XX on address our on first our At in the update potential track April, Slide more would we last third August, call COVID-XX peak programs update briefly entered had impact our the have post the operations. in and throughout financial
October few rates occupation have in in in building And lag, increase and through followed. we U.S. with and in substantial into weeks seen rates September November, accelerating and hospitalization increases and However, a infection a in the Europe ICU
company patients reaction, was October. of the end a in areas enroll have all the few In increased Europe From geographic of what public first us concentration of cases of the peak through helped restrictions across on U.S. life perspective, the pandemic in
of that impacted. sites our U.S. not trial most clinical period, were During
the in country, now, disruptions of across has already U.S. for infections with spread Going into risk winter the an entire the increased. broad trial
final of We closely, lines on chain and supply transatlantic enrollment with supply to logistics be, if and uninterrupted our time follow of our remain ensure as to will into continental ensure and have need operations. deliveries teams for to centers products That hard our we're This timely the and well our track. may situation working and includes essential goods ultimately said, services adjust trials. as patient leukapheresis
patient ensuring on safety is in trials. focus and key data our integrity our always, As
a Phase enrollment While we this trial been to for year. delay patient programs, our impacted, date, ongoing not our earlier with experience AUTOX and significantly clinical lead AUTOX, I have AUTOX did in
be development to to clinical in data been our to initial stabilized, we the so tumor preclinical XXXX. situation continue I now, With impacted, have available AUTOX minimally solid to in respect and from far XXXX. we AUTOX, continue AUTOXNG expect for to enter and expect this and and has programs, study However, our Phase these programs,
Our in the begin multiple to AUTOX of first pediatric on with AUTOX/XX in ALL in track in is study the remains clinical start and year. fourth next to first quarter, half myeloma due
AUTOX, of moving at Slide know, you our end across Ib/II with data our pivotal highlights adult had potential ESMO lymphoblastic corporate data respect Phase So relapsed/refractory year. with on for to positive We've busy our by programs we into as have patients our acute are AUTOX. to with program update targeting leukemia quarter and of clinical commenced next starting AUTOX the portfolio, With X. a enrollment to and
situation. As contingent COVID-XX be on indicated will before, time evolving the lines
on the updates analyst has ALLCARXX We're and presentations release study been planning at oral AUTOX an AUTOX of ALEXANDER for accepted for the host study call ASH. the the Finally, presentations ASH. for following at to
We on update details will the coming in you weeks. the
a profile, would leukemic important to safety cope pressure the second, transformational put ALL: bone a adult on the to our growth in to long for particularly very adult rapid patients. recap I cells outcome; lead a the and for which AUTOX first, and with designed long-term program, AUTOX, like leukemia features is marrow; X ALL. is high antileukemic key level of stand-alone tolerable in get on combine Moving persistence third, the to of to in briefly elderly therapy to X. very required Slide a activity
and inotuzumab, U.S. approximately the blinatumomab options. In reach X other the X,XXX within also the treatment every patients terms requiring or of European often transplant market options year having and top chemotherapy therefore, failed of the their cell countries, end and opportunity stem
patients, and we about in we a the At high maintaining this standard as significant reached I is limited setting. we care who without medical while think of ALL, pressure for transplant. X. comparable AUTOX Phase adult our active see provide are From we will safety these Xx very therapies as could that patients profile. with longer competitive remission XX a at first have molecular experience, approved Currently, ASH need there a complete blinatumomab, receiving in Data for a CAR-T no opportunity months show follow-up. Slide EHA,
turning to based Slide enrollment pivotal adult on program, this the AUTOX-ALX, So we have in into started ALL. X, data,
'XX, As a a single-arm survival disruptions We're study and XXX pivotal Phase of comprises molecular no endpoint trial event-free Ib the to response. data is endpoints patients. complete of by approximately the clinical has a primary remission The of and relapsed/refractory reminder, study include COVID targeting conduct. remission end running, program rates, secondary the and assuming duration complete rate
across in Exploratory studies CNS In the academic exploring as in this lymphoma QX a XX, Slide planned on include B-cell I franchise. Finally, study AUTOX collaboration year highlight partners other our with ALL. malignancies. wanted primary obviously the broader pediatric UCL, we're potential AUTOX with well AUTOX/XX of to start as at
a to dual approval. product medical CAR-T as products liso-cel, now Let's targeting approved, to Kymriah, for with patients the risks high like B-cell treatment large to AUTOX JCAR-XX, lymphoma. diffuse in designed a is indication due XX, of and I Slide switch Two gears about plus talk designed is where is to and CAR-T are patients antigen NHL of minimize relapse that Yescarta the pending is last-line or setting the need. XX,XXX turn with AUTOX, approximately largest DLBCL program very loss. would otherwise a with known
of inhibition short to of cover using as PD-LX addition design of potential checkpoint cause second unique pembrolizumab In AUTOX, mediated to a relapse. molecular the we're a counteract also
despite neurotoxicity robust and patient syndrome achieving XX, release rate XX cytokine ESMO, across neurotoxicity and combined study. as profile. XX%, high-grade Slides high rates with all the On Both was experienced AUTOX cytokine at of expansion, very level rate safety XX%. CAR-T release and CR those the syndrome. the no patients complete a reported response cohorts, In was remission showed favorable are complete had remissions, and any low or Across overall a
high therapies. the XX% with Turning clinical good DLBCL patients a to of the small with concentration to and products XX% safety the up important therapies. This outside B-cell number profile patients. majority underpenetrated of vast treated of Medicare receiving of a in centers of are the is lymphoma CAR-T patients such treated large very activity on diffuse setting. level all make particularly over patients contrast, Slide CAR-T of a XX. centers of as illustrates mostly in Combining were excellence in only XXXX large market outpatient accredited In certified administer in how is excellence portion these Also, DLBCL of centers of
provide patients of XX% All a in opportunity AUTOX than due significant to here. challenges solution in see are for less on a reimbursement the to A part treated can this creates However, Medicare all, side. the you
to Slide XX. So let's turn
As a of AUTOX feasibility to designed in reminder, setting. is cohort further outpatient assess ALEXANDER use the the expansion the
other at as cohorts. in ASH efficacy As I and safety an data across the update mentioned, completed outpatient to expect from our provide well as core we patients treated have
Turning to Slide #XX.
to discussed, have level use first-in-class is care. CAR settings CDXX, combine the across high dual potential of good we for a of activity targeting clinical with As a all safety CDXX AUTOX profile designed
on first the XXXX. XX, Finally, pipeline trials Most developing of the programs programs remind I we're next-generation broader of set the the clinical like are move Slide to at you would company. proud be of to to into in
in addressing our AUTOX/XX antigen first relapse the pediatric on loss-driven strong ALL. pediatric The for AUTOX data is targeting CDXX and dual program, building
for With Andrew? call update. will quarter turn that, the I to third Andrew over financial the XXXX
